For locally advanced or recurrent metastatic breast cancer that is resistant to systemic therapy, radiotherapy (RT) may be considered as the preferred treatment option when the lesion is unresectable, or the patient is not suitable for surgery. This study aim to evelatuate the local control of radical dose RT or new RT technique (such as patially fractionated radiation therapy, SFRT) for the locally advanced or recurrent metastatic breast cancer.
Eastern Cooperative Oncology Group (ECOG) performance status of 0-2;
Locally advanced or recurrent metastatic breast cancer, pathologically confirmed;
At least one extracranial measurable lesion suitable for radiotherapy;
Signature of informed consent form.
Pregnant or lactation women;
Severe concomitant conditions, including persistent or active infections, symptomatic congestive heart failure, unstable angina pectoris, and serious arrhythmias et al.
Single group
Radical dose radiotherapy
RadiationRadical dose is delivered for the patients. SFRT is recommended for the patients with bulky tumor (such as ≥ 5cm). SFRT is delivered with 12-20Gy (1 fraction) followed by external beam radiation therapy (EBRT) with EQD2≥60Gy.
Overall Response Rate (ORR)
Overall Response Rate (ORR)
Local control
Progression-Free Survival (PFS)
Overall Survival (OS)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
